Systemic Lupus Erythematosus
Original Editors - Alli Christian from Bellarmine University's Pathophysiology of Complex Patient Problems project. Top Contributors - Alli Christian, Elaine Lonnemann, Kim Jackson, Lucinda hampton and Rachael Lowe - Elaine Lonnemann
- 1 Definition/Description
- 2 Epidemiology
- 3 Etiology
- 4 Pathological Process
- 5 Diagnosis
- 6 Medical Management
- 7 Physical Therapy Management
- 8 Prognosis
- 9 Resources
- 10 References
Systemic lupus erythematosus (SLE) is an inflammatory connective tissue disease with variable manifestations.
- SLE may affect many organ systems with immune complexes and a large array of autoantibodies, particularly antinuclear antibodies (ANAs).
- Although abnormalities in almost every aspect of the immune system have been found, the key defect is thought to result from a loss of self-tolerance to autoantigens.
- It is a disease characterized by relapses, flares, and remissions.
- Common manifestations, in addition to the malar rash, include cutaneous photosensitivity, nephropathy, serositis, and polyarthritis.
- The overall outcome of the disease is highly variable with extremes ranging from permanent remission to death.
- There is a strong female predilection in adults, with women affected 9-13 times more than males. In children, this ratio is reversed, and males are affected two to three times more often.
- Can affect any age group - the peak age at onset around the 2nd to 4th decades, with 65% of patients presenting between the ages of 16 and 65 years (i.e. during childbearing years).
- Disease is more common in childbearing age in women however it has been well reported in the pediatric and elderly population. SLE is more severe in children while in the elderly, it tends to be more insidious onset and has more pulmonary involvement and serositis and less Raynaud's, malar rash, nephritis, and neuropsychiatric complications
- Studies have indicated that although rare, lupus in men tends to be more severe.
- Prevalence varies according to ethnicity with ratios as high as 1:500 to 1:1000 in Afro-Caribbeans and indigenous Australians, down to 1:2000 in Caucasians.
The cause of lupus erythematosus is not known.
- A familial association has been noted that suggests a genetic predisposition, but a genetic link has not been identified. Approximately 8% of patients with SLE have at least one first-degree family member (parent, sibling, child) with the disease.
- Environmental factors - Ultraviolet light (increased keratinocyte apoptosis), infection (via molecular mimicry and bacterial CpG motifs), smoking (odds ratio (OR): 1.56 in current smokers, 1.23 in ex-smokers), environmental pollutants (silica) and intestinal dysbiosis (ie digestive disturbances, frequent gas or bloating, feel bloated on most days of the week, abdominal cramping, diarrhea, and constipation) are all known risk factors for SLE.
- Hormonal abnormality and ultraviolet radiation are considered possible risk factors for the development of SLE.
- Some drugs have been implicated as initiating the onset of lupus-like symptoms and aggravating existing disease; they include hydralazine hydrochloride, procainamide hydrochloride, penicillin, isonicotinic acid hydrazide, chlorpromazine, phenytoin, and quinidine.
- Possible childhood risk factors include low birth weight, preterm birth, and exposure to farming pesticides.
SLE can affect multiple components of the immune system, including the
- Complement system (ie a part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells from an organism, promote inflammation, and attack the pathogen's cell membrane),
- T-suppressor cells
- Cytokine production.
Emerging evidence has demonstrated a key player in the generation of autoantigens in SLE is the increase in generation (i.e. increased apoptosis) and/or decrease in clearance of apoptotic cell materials (i.e., decreased phagocytosis).
Results in generation of autoantibodies, which may circulate for many years prior to the development of overt clinical SLE. The disease tends to have a relapsing and remitting course.
SLE has a myriad of clinical features:
- CNS manifestations of systemic lupus erythematosus (CNS lupus): neuropsychiatric events can occur in ~45% (range 14-75%) of cases
- gastrointestinal manifestations of systemic lupus erythematosus: there may be GI involvement in ~20% of cases
- musculoskeletal manifestations of systemic lupus erythematosus
- renal manifestations of systemic lupus erythematosus
- thoracic manifestations of systemic lupus erythematosus.
All of the below symptoms might not be present at the initial diagnosis of SLE, but as the disease progresses more of a person’s organ systems become involved.
The most common symptoms associated with SLE are:
- Constitutional symptoms (fever, malaise, fatigue, weight loss): most commonly fatigue and a low-grade fever
- Achy joints (arthralgia)
- Arthritis (inflamed joints)
- Pulmonary involvement (symptoms include: chest pain, difficulty breathing, and cough)
- Kidney involvement (lupus nephritis)
- Sensitivity to the sun or light (photosensitivity)
- Hair loss
- Raynaud’s phenomenon
- CNS involvement (seizures, headaches, peripheral neuropathy, cranial neuropathy, cerebrovascular accidents, organic brain syndrome, psychosis)
- Mouth, nose, or vaginal ulcers”
- The most common signs and symptoms of SLE in children and adolescents are: "fever, fatigue, weight loss, arthritis, rash, and renal disease."
There are many visceral systems can be affected from SLE, but the extent of the body's involvement differs from person to person. Some people diagnosed with SLE have only few visceral systems involved, while others have numerous systems that have been affected by the disease.
- Arthritis- typically affects hand, wrists, and knees
- Tendon ruptures
- Swan-neck deformity
- Ulnar drift
Central Nervous System
- Emotional instability
- Cerebrovascular accidents
- Cranial neuropathy
- Peripheral neuropathy
- Organic brain syndrome
- Glomerulonephritis -inflammatory disease of the kidneys
- Kidney failure
- Cutaneous vasculitis
- Hair loss
- Raynaud's phenomenon
- Mucosal ulcers
- Ulcers--Throat & Mouth
- Ulcerative colitis/Crohn's disease
- Peptic ulcers
- Autoimmune Hepatitis 
Include:Fibromyalgia. Atherosclerosis  Lupus Nephritis- leads to End Stage Renal Disease (ESRD) Anemia Some types of cancers (especially non-Hodgkin's lymphoma and lung cancer)   Infections Hypertension Dyslipidemia Diabetes Mellitus Osteoporosis Avascular Necrosis 
The diagnosis of SLE may be made be if four of eleven ACR (American College of Rheumatology) criteria are present, either serially or simultaneously 2. These criteria were initially published in 1982 but were revised in 1997.
The goal of treatment in SLE is to prevent organ damage and achieve remission. The choice of treatment is dictated by the organ system/systems involved and the severity of involvement and ranges from minimal treatment (NSAIDs, antimalarials) to intensive treatment (cytotoxic drugs, corticosteroids).
- Patients with SLE should be well educated on the disease pathology, potential organ involvement including brochures, and the importance of medication and monitoring compliance.
- Stress reduction techniques, good sleep hygiene, exercises, and use of emotional support shall be encouraged.
- Smoking can worsen SLE symptoms - educated about the importance of smoking cessation.
- Dietary recommendations - avoiding alfalfa sprouts and echinacea and including a diet rich in vitamin-D.
- Photoprotection is vital, and all patients with SLE shall avoid direct sun exposure by timing their activities appropriately, light-weight loose-fitting dark clothing covering the maximum portion of the body and using broad-spectrum (UV-A and UV-B) sunscreens with a sun protection factor (SPF) of 30 or more (see image R)
Physical Therapy Management
Exercise is beneficial for patients with SLE because it decreases their muscle weakness while simultaneously increases their muscle endurance. Physical therapists can play an important role for patients with SLE during and between exacerbations. The patient's need for physical therapy will vary greatly depending on the systems involved.
- Education: It is essential for patients with skin lesions to have appropriate education on the best way to care for their skin and to ensure they do not experience additional skin breakdown.
- Aerobic Exercise: One of the most common impairments that patients with SLE experience is generalized fatigue that can limit their activities throughout the day. Graded aerobic exercise programs are more successful than relaxation techniques in decreasing the fatigue levels of patients with SLE. Aerobic activity causes many with SLE to feel much better. The aerobic exercise program may consisted of 30-50 minutes of aerobic activity (walking/swimming/cycling) with a heart rate corresponding to 60% of the patient's peak oxygen consumption. Both aerobic exercise and range of motion/muscle strengthening exercises can increase the energy level, cardiovascular fitness, functional status, and muscle strength in patients with SLE (aerobic exercise for 20-30 minutes at 70-80% of their maximum heart rate,3 times a week for 50 minutes sessions).
- Energy Conservation: Physical therapists can educate patients on appropriate energy conservation techniques and the best ways to protect joints that are susceptible to damage.
- Additionally, physical therapists and patients with SLE should be aware of signs and symptoms that suggest a progression of SLE including those associated with avascular necrosis, kidney involvement, and neurological involvement.
Recent advances in diagnosis and treatment strategies has resulted in a survival improvement from 5-year survival at 40-50% in the 1950s up to a 10-year survival now estimated at 80-90%. Nevertheless, patients with SLE have a standardised mortality ratio of 3.
Early deaths in disease course are usually due to active disease and immunosuppression while late deaths tend to arise from coronary artery disease and SLE or treatment complications (e.g. end-stage kidney disease from lupus nephritis).
- Radiopedia SLE Available from:https://radiopaedia.org/articles/systemic-lupus-erythematosus (last accessed 5.6.2020)
- Medscape SLE Available from:https://emedicine.medscape.com/article/305578-overview (last accessed 5.6.2020)
- Julkunen H. Systemic lupus erythematosus (SLE). Epidemiology. 2018 Sep 3.Available from:https://www.ncbi.nlm.nih.gov/books/NBK535405/ (last accessed 5.6.2020)
- Nursing central SLE Available from:https://nursing.unboundmedicine.com/nursingcentral/view/Diseases-and-Disorders/73651/all/Lupus_Erythematosus (last accessed 5.6.2020)
- Goodman CC, Fuller KS. Pathology: Implications for the Physical Therapist. 3rd edition. St. Louis, Missouri: Saunders Elsevier, 2009.
- "Handout on Health: Systemic Lupus Erythematosus". www.niams.nih.gov. June 2016.(Accessed 28 April 2019).
- Tucker LB. Making the diagnosis of systemic lupus erythematosus in children and adolescents. Lupus; 16: 546-549. 2007.
- Lupus Foundation of America. How lupus affects the body page. Website updated: 2010. Website accessed: February 17, 2010.
- Goodman CC and Synder TK. Differential Diagnosis for Physical Therapists: Screening for Referral. 4th edition. St. Louis, Missouri: Saunders Elsevier, 2007.
- Becker-Merok A, Nossent JC. Prevalence, predictors, and outcomes of vascular damamge in systemic lupus erythematosus. Lupus; 18: 508-515. 2009.
- Bertsias G, Gordon C, Boumpas DT. Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future- the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus; 17: 437-442. 2008.
- Wingard R. Increased risk of anemia in dialysis patients with comorbid diseases. Nephrology Nursing Journal; 31 (2): 211-214. 2004.
- Medical Foundation for Medical Education and Research. Mayo Clinic: Lupus Page. www.mayoclinic.com. Updated October 20, 2009. Accessed February 17, 2010.
- Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus.Arthritis & Rheumatism 2005;52(5):1481–90.
- Tench CM, McCarthy J, McCurdie I, White PD, D'Cruz DP. Fatigue in systemic lupus erythematosus: a randomized control trial of exercise. Rheumatology; 42: 1050-1054. 2003. (Level of evidence 1B)
- Ramsey-Goldman GR, Schilling EM, Dunlop D, Langman C, Greenland P, Thomas RJ, Chang RW. A pilot study on the effects of exercise in patients with systemic lupus erythematosus. Arthritis Care and Research; 13(5): 262-269. 2000. (Level of evidence 2B)